Physician profile
Asya Braginsky
NPI 1568488948
$4,502.75
in general payments reported to CMS, 2019-2025
25 companies · $825 in 2025
The $825 reported for 2025 was more than what 77% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $638 · 2022: $1,000 · 2023: $911 · 2024: $1,129 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,864.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $643.59 | 2022-2024 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $643.52 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $541.23 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.83 | 2021-2025 | Jardiance |
| Amgen INC. | $284.81 | 2021-2025 | Repatha, Repatha |
| Medtronic, INC. | $254.72 | 2022-2025 | Symplicity G3, Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $243.07 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $221.43 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $178.38 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $169.92 | 2021-2025 | Farxiga, Lokelma |
| Amarin Pharma, INC. | $168.83 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $124.99 | 2025 | Zenpep |
| Alnylam Pharmaceuticals INC. | $124.74 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $118.90 | 2022 | |
| Boston Scientific Corporation | $105.54 | 2021-2023 | Watchman Access System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.82 | 2021-2024 | Lifevest |
| Heartflow, INC. | $63.07 | 2025 | |
| Edwards Lifesciences Corporation | $54.26 | 2022-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lexicon Pharmaceuticals, INC. | $50.23 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $25.54 | 2024 | Arcalyst |
| Lilly USA, LLC | $25.09 | 2025 | Zepbound |
| Recor Medical INC | $19.05 | 2025 | Paradise Ultrasound Renal Denervation System |
| Esperion Therapeutics, INC. | $18.73 | 2024 | Nexletol |
| Irhythm Technologies, INC. | $16.41 | 2024 | Zio Xt Patch, Zio Monitor |
| Scpharmaceuticals INC. | $15.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asya Braginsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.